Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies

Details for Australian Patent Application No. 2008247451 (hide)

International Classifications

Event Publications

3 December 2009 PCT application entered the National Phase

PCT publication WO2008/137803 Priority application(s): WO2008/137803

2 September 2010 Amendment Made

The nature of the amendment is: Amend the priority details from INID(31) 11/874,869 INID 18.10.07 INID US to INID(31) 61/190,044 INID 18.10.07 INID US

3 May 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.